Coordinated targeting of S6K1/2 and AXL disrupts pyrimidine biosynthesis in PTEN-deficient glioblastoma

Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2024-10-18
DOI
https://doi.org/10.17615/mqdx-6c46
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Coordinated targeting of S6K1/2 and AXL disrupts pyrimidine biosynthesis in PTEN-deficient glioblastoma

Maria Czyzyk-Krzeska, Soma Sengupta, Catherine A. Behrmann, Ady Kendler et al.
UNC Libraries
PI3K/AKT/mTOR signaling in cancer
article

Coordinated targeting of S6K1/2 and AXL disrupts pyrimidine biosynthesis in PTEN-deficient glioblastoma

Maria Czyzyk-Krzeska, Soma Sengupta, Catherine A. Behrmann, Ady Kendler, Subrahmanya Vallabhapurapu, Jann Nagina Sarkaria, Xiaoyang Qi, P.N. Sarma, Pier Paolo Scaglioni, Nicholas A. Clark, Cristina Andreani, Biplab Dasgupta, Mario Medvedovic, Collin Wetzel, David R. Plas, James Reigle, Jarek Meller, Kelli N. Ennis, Kate M. Von Handorf
article en

Abstract

Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM.

UNC Libraries
University of North Carolina at Chapel Hill (US)
University of Cincinnati, Broad Institute, National Institutes of Health
Zero hunger
Openalex Percentile: Top 83%
PI3K/AKT/mTOR signaling in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.